5,989
Participants
Start Date
May 31, 2000
Primary Completion Date
April 30, 2001
Full dose TNK-tPA
Half dose TNK-tPA
Heparin
Enoxaparin
Abciximab
Lead Sponsor
Boehringer Ingelheim
INDUSTRY